NCT07151378View on ClinicalTrials.gov

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

September 22, 2030

Study Completion Date

September 22, 2030

Conditions
PARKINSON DISEASE (Disorder)
Interventions
DRUG

LECIG (levodopa, carbidopa, entacapone intestinal gel)

intestinal L-Dopa + entacapone (Lecigon®)

DRUG

Best oral medication

Best oral medication

Trial Locations (1)

72076

Centre for Neurology, Department forNeurodegenerative Disease, and Hertie-Institute forClinical Brain Research, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER